Skip to main content
Premium Trial:

Request an Annual Quote

And It Did Work

The New York Times has a Q&A with Brian Druker, the researcher who developed Gleevec. When Druker started out as an oncologist in the '80s, "cancer was seen as something like a light switch that was stuck in an 'on' position. You were given a baseball bat, which was chemotherapy, and told to knock the light out with the bat," he says. That led him to study how cell growth is regulated and, eventually, brought him to Gleevec, which is now used by about 200,000 people. "I understood that this project was too good to give up on. My patients needed me to do something to help them. I did everything I could by getting them a drug I thought would work," Druker says.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.